All In Biotech

Drug Trial Radar · NCT01380743

Drug-drug Interaction Study

An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease

Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Oct 31, 2011

Primary completion

Jan 4, 2013

Study completion Jan 4, 2013

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.

Conditions

  • Pompe Disease

Interventions

  • duvoglustatDrug

    Single oral dose

  • rhGAADrug

    Single intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 after dosing up to Day 60
  2. Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
  3. PK: Time To The Maximum Plasma Concentration (Tmax) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
  4. PK: Elimination Half-life (T1/2) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
  5. PK: Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUC0-t) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
  6. PK: AUC From Time 0 Extrapolated To Infinity (AUCinf) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Orange, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Kansas City, Kansas

  • Site not named

    Great Falls, Montana

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Springfield, Virginia

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Paris, France

  • Site not named

    Salford, United Kingdom

  • Site not named

    London, Queen Square, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.